Format

Send to

Choose Destination
Clin Cancer Res. 2016 Apr 1;22(7):1777-86. doi: 10.1158/1078-0432.CCR-15-1250. Epub 2015 Dec 2.

The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer.

Author information

1
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Transitional Year Program, Beaumont Hospital-Dearborn, Dearborn, Michigan.
2
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
3
James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland.
4
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
5
Department of Radiation Oncology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania.
6
Department of Urology, Mayo Clinic, Rochester, Minnesota.
7
GenomeDx Biosciences Inc., Vancouver, British Columbia, Canada.
8
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
9
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan. Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan. ffeng@med.umich.edu.

Abstract

PURPOSE:

There is a clear need to improve risk stratification and to identify novel therapeutic targets in aggressive prostate cancer. The goal of this study was to investigate genes with outlier expression with prognostic association in high-risk prostate cancer patients as potential biomarkers and drug targets.

EXPERIMENTAL DESIGN:

We interrogated microarray gene expression data from prostatectomy samples from 545 high-risk prostate cancer patients with long-term follow-up (mean 13.4 years). Three independent clinical datasets totaling an additional 545 patients were used for validation. Novel prognostic outlier genes were interrogated for impact on oncogenic phenotypes in vitro using siRNA-based knockdown. Association with clinical outcomes and comparison with existing prognostic instruments was assessed with multivariable models using a prognostic outlier score.

RESULTS:

Analysis of the discovery cohort identified 20 prognostic outlier genes. Three top prognostic outlier genes were novel prostate cancer genes; NVL, SMC4, or SQLE knockdown reduced migration and/or invasion and outlier expression was significantly associated with poor prognosis. Increased prognostic outlier score was significantly associated with poor prognosis independent of standard clinicopathologic variables. Finally, the prognostic outlier score prognostic association is independent of, and adds to existing genomic and clinical tools for prognostication in prostate cancer (Decipher, the cell-cycle progression signature, and CAPRA-S).

CONCLUSIONS:

To our knowledge, this study represents the first unbiased high-throughput investigation of prognostic outlier genes in prostate cancer and demonstrates the potential biomarker and therapeutic importance of this previously unstudied class of cancer genes.

PMID:
26631616
DOI:
10.1158/1078-0432.CCR-15-1250
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center